J.Safra Asset Management Corp Vaxcyte, Inc. Transaction History
J.Safra Asset Management Corp
- $883 Million
- Q1 2024
A detailed history of J.Safra Asset Management Corp transactions in Vaxcyte, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 81 shares of PCVX stock, worth $6,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
81Holding current value
$6,300% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
268Shares Held
97.1MCall Options Held
202KPut Options Held
147K-
Vanguard Group Inc Valley Forge, PA9.74MShares$757 Million0.01% of portfolio
-
Black Rock Inc. New York, NY9.51MShares$740 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07.67MShares$597 Million0.29% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$383 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.14MShares$322 Million0.07% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.61B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...